At a glance
- Argireline (acetyl hexapeptide-8) is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 47 publications mentioning it, including 3 randomized controlled trials and 3 animal-only studies.
- ClinicalTrials.gov lists 7 registered studies testing it (0 active).
- FDA’s adverse event system (FAERS) has no reports mentioning it.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Mechanistic understanding and peptide ingredient screening for type III collagen via biological knowledge graph and molecular docking.
- Effects of Botulinum Toxin Type A and Argireline on Dermal Collagen Remodeling and Skin Biology in a Flap Model.
- DES-mediated self-assembled polypeptides: Synergistic neuromuscular signaling inhibition for anti-aging.
- Ex Vivo Evaluation of Skin Permeability Enhancement Using TargetCool in Human-Derived Skin Tissue Models.
- The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies.
- Cosmetic potential of Ganoderma lucidum (Reishi) extract in a topical cream formulation.
- Thermostable hyaluronic acid-based dissolving microneedles with high-loading capacity: design, optimization, and transdermal delivery of anti-aging ingredients.
- Fluorous oligoarginines as supra-enhancers for intracellular and transdermal peptide delivery.
- Oligomeric hyaluronic acid-modified liposomes effectively improved skin permeability and anti-ageing activity of ellagic acid.
- Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 7
- Active
- 0
- With posted results
- 2
Conditions studied
| Study | Status | Phase | Start |
|---|---|---|---|
| AI-Personalized Skincare Regimen for Facial Photoaging in Women | Completed | N/A | September 30, 2025 |
| A Clinical Trial to Evaluate the Effects of an Eye Serum on Improving the Appearance of the Periorbital Area | Completed | N/A | August 21, 2023 |
| Investigating the Wrinkle Reduction Potential of a Novel Compounded Skin Care Cream | Completed | Early phase 1 | April 1, 2019 |
| Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin | Completed | N/A | Jan 2016 |
| Acetyl Hexapeptide-8 for Blepharospasm | Terminated | Phase 2 | Nov 2012 |
| A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm | Completed | Phase 1, Phase 2 | Jul 2009 |
| Argireline in Treatment of Periorbital Wrinkles | Completed | Phase 3 | Mar 2009 |
All 7 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
No FAERS reports mention this peptide.
FDA prescribing information
Official US prescribing information. Dosing sections are intentionally not shown.
- Chanvida Broad Spectrum BB Cream
- STYE EYE RELIEF SERUM
- XIMONTH GLP-1 Patches
- Anti-wrinkle eye cream
- Stretch Marks cream
Source: DailyMed / openFDA
Change history
No changes since monitoring began on October 30, 2026.